The company has opened an office in Boston to support its increasing US clinical development, partnering and fund-raising activities.
The new office is at the CIC in Boston, Massachusetts which has been a home for great entrepreneurs leading fast-growing companies since 1999, describes the company.
“Boston is at the heart of one of the world’s biggest biotech clusters, and we’re delighted to become part of that vibrant community as we invest in this infrastructure and accelerate towards Phase 2 trials of our innovative armed oncolytic viruses,” says TILT Biotherapeutics’ CEO, Akseli Hemminki.
“Help to drive our US clinical development”
This follows the company’s collaborations with US pharma partners and leading cancer centers. The current US clinical trials are run in collaboration with MSD and the Merck-Pfizer-Alliance.
“Our newly established US operations will help to drive our US clinical development in this leading global pharmaceutical market, including lining up several new clinical trial centers, building on our work with the Mayo Clinic, and supporting forthcoming IND filings,” says TILT Biotherapeutics’ COO, and President of US operations, Aino Kalervo.